About us
Slate Therapeutics develops drug device combination product for the treatment of chronic sinusitis; our vision is to help Sinusitis patients to heal faster & better for longer periods. We intend to overcome the limitations of other alternative treatments by providing durable therapeutic treatment of the sinuses locally without the need for leaving any implant behind.
The need
5-12 percent of the world population suffer from Sinusitis (Over 30 million in the US alone), and treatment for the condition is sub-par. It relies on ineffective nasal sprays and, when this fails, turns to Functional Endoscopic Sinus Surgery (FESS). While the surgery relieves symptoms, disease recurrence is common. Companies use biodegradable sinus implants for drug delivery to improve the outcome of sinus surgeries. However, these implants are uncomfortable and come with risks, such as swallowing the implant, pain/pressure/headache, and foreign body response, including granulation tissue formation. Furthermore, they may require the use of saline irrigations and nasal sprays to keep the implant moist. Other solutions, such as drug-coated balloons have failed, due to the complex architecture of sinus cavities.
Companies recognize the need to deliver sinus solutions without an implant but have failed to do so successfully.
Our technology
Slate Therapeutics developed a novel Sol-Gel Hydrogel platform consisting of slow eluting microspheres loaded with MF for local delivery. The Sol-Gel Hydrogel can easily be sprayed or extruded to form either mucoadhesive gel microdroplets or a thin film (dressing) post FESS or in surgery naïve sinuses.
Unlike current stent modalities, Slate’s technology is designed to provide sustained therapy at the point of disruption, maintaining patency, expediting healing, and manage the onset of polyps. Our initial hydrogel formulation already demonstrated over three weeks of suspended release to target tissue, positioning us competitively with Medtronic’s Propel and Sinuva sinus stents. Slate’s technology, unlike its competitors, offers Sinus Care with Comfort, Precision, and Versatility, promoting sustained healing without disrupting basal activity.
The gel will be administered into the nasal cavity using an approved existing delivery system compatible with Endoscopic and FESS delivery lumen and suitable for our formulation.
The Market
- Sinus inflammatory disorder affects 5-12% of the world population; results in ~600K sinus surgeries/ year in the US alone.
- Most chronic sinusitis patients fail conventional medical treatment (nasal sprays), but do not get surgery.
- The treatment address both the Surgical as well as the more significant preventative markets
- Global Sinus Market is forecasted to reach $50B in 2024.
Team
- Matan Soll (CEO)– Investor and innovation lead at Medison Ventures and Medison Pharma, leading due diligence for investments in Digital Health, Diagnostics, Medical Devices and Biotech. Co-founder & CTO of Corryzyme, which developed novel nanoparticles for the treatment of late-stage prostate cancer. PhD of Chemistry from the Technion and an MBA from the Azrieli Start Up program at the Technion.
- Yohan Hazot (CTO)– a seasoned Pharma Executive and consultant, who brings to the table over 15 years of experience focused on drug development and R&D management. He’s played a critical role in various positions to 2 FDA approvals for topical drugs, Amzeeq® and Zilxi® during his tenure at VYNE Therapeutics, Inc. and Foamix Pharmaceuticals. Yohan also led the development of the VYNE Therapeutics’ early to clinical-stage CMC programs for NCE and 505(b)2 drug products from early development to first-in-human and Phase 2 clinical studies. An accomplished inventor with 14 patent families and over 130 patent applications to his name, worldwide. With his experience in CMC, regulatory filings, tech-transfer, project management, IND and NDA submissions, and experience leading global contract manufacturing and research organization management. MSc in Biochemistry and Biotechnology from the National Institute of Applied Sciences (Lyon, France).
- Dr. Eitan Konstantino (co-founder, Strategic Partner, R&D, Design)– Eitan has made significant contributions to the field of MedTech, with more than two decades in R&D, defined by numerous breakthrough inventions. Eitan is best known for inventing and developing stents, angioplasty balloons and vascular devices acquired or distributed by top-tier multinationals including: Medtronic, Teleflex, Philips, J&J Cordis, and Boston Scientific. His products are commercially available in the majority of US hospitals and have generated a cumulative revenue which approaches $1B. Eitan founded, invested in and led multiple medical device companies in the US and Asia, from concept through sales. He has led several international M&A, IPO and licensing transactions and has raised more than $200M in capital. Eitan served as co-Chairman of ASTM/FDA task force for endovascular standards and was recognized by the White House, Office of President Obama as a medical device expert. Eitan takes a global approach to innovation and was appointed advisor to Spring Singapore MedTech network of advisors and expert panelist for grants awarded by A*Star: Singapore government Agency for Science, Technology & Research. Eitan holds a PhD in Mechanical Engineering from the Technion-Israel Institute of Technology. While at the Technion, he won the Rothschild Creativity Award, and the Schwartz Outstanding Achievement Award.
- Gary Binyamin, PhD (Co-Founder)- General Manager of G Vascular USA; CSO of Tech, TriReme Medical; CEO, Neodyne Biosciences; Discovery Eng, Galileo Pharma;, Fellowship, Stanford, PhD. UT Austin, BSc. Univ of Illinois
- Eran Vickus (Co-Founder, BOD)- CEO & co-founder of Rev-Medical Inc; founder of Vmedical, CEO & CCO, Angioslide; S&M, UltraShape, R&D Eng., KST Dynamics; QA specialist, Adante Medical. MBA and a Biomedical Eng. From Tel Aviv and Ben Gurion Universities
- Tanhum Feld (Co-Founder) – Co-founder & CDO, SanoV; co-founder & CDO, Trireme Medical; co-founder & CDO Quattro Vascular; Founder, Angioscore. MSc. Technion Israel Institute of Technology.
- Manzooma Kablan (formulation Chemist)– The leading formuklation chemist at New Phase ltd, managed QA and QC of all batches. Hold a position of a QA/QC professional at TEVA Pharmaceuticals, developing methods and releasing batches. Holds BSc and in Pharmaceutical Chemistry from Azrieli College of Engineering Jerusalem.
Contact information
Dr. Matan Soll, CEO
Mobile: +972-523662298
Office: +972-4-609-8628
Fax: +972-4-609-8600
Email: matan@slatetherapeutics.com